Evidence map›Paper›PMID 37452162›Full record

ArticleDiscover oncology2023

Veillonella parvula promotes the proliferation of lung adenocarcinoma through the nucleotide oligomerization domain 2/cellular communication network factor 4/nuclear factor kappa B pathway.

Wen Zeng, Yuhuan Wang, Zhe Wang, Mengge Yu, Kang Liu, Chengzhu Zhao, Yiyun Pan, Shudong Ma

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The role ofFrontiers in oral health · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Frontiers in immunology · 2025
    Article
  9. Article
  10. Association Between Oral Microbiota and Gastrointestinal/Extra-Gastrointestinal Diseases.The Korean journal of helicobacter and upper gastrointestinal research · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wen Zeng *Oncology Research Institute, Ganzhou Cancer Hospital, Gannan Medical University, Huayuan Road No.19, Shuidong Town, Zhanggong District, Ganzhou, 341000, Jiangxi Province, China.
Yuhuan Wang *Department of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Baiyun District, Guangzhou, 510000, Guangdong Province, China.
Zhe Wang *Department of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Baiyun District, Guangzhou, 510000, Guangdong Province, China.
Mengge YuDepartment of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Baiyun District, Guangzhou, 510000, Guangdong Province, China.
Kang LiuThe First Clinical College, Gannan Medical University, Ganzhou, Jiangxi Province, China.
Chengzhu ZhaoDepartment of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Baiyun District, Guangzhou, 510000, Guangdong Province, China.
Yiyun PanOncology Research Institute, Ganzhou Cancer Hospital, Gannan Medical University, Huayuan Road No.19, Shuidong Town, Zhanggong District, Ganzhou, 341000, Jiangxi Province, China. 947271147@qq.com.
Shudong MaDepartment of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Baiyun District, Guangzhou, 510000, Guangdong Province, China. hxingwei2020@yeah.net.
Southern Medical University · CNGannan Medical University · CNNanfang Hospital · CN

Funding

Ganzhou Municipal Health Care Committee Municipal Research Program Project 2020-2-47National Natural Science Foundation of China 82272977Natural Science Foundation of Guangdong Province 2021A1215011719Projects of Traditional Chinese Medicine Science and Technology Plan of Jiangxi Province 2021B363Science and Technology Project of Jiangxi Provincial Health Commission 202212543
6 · The paper itself

Abstract

Enrichment of Veillonella parvula in the lung microbiota is strongly associated with non-small cell lung cancer (NSCLC) and induces the progression of lung adenocarcinoma in vivo, but its actual role and mechanism remain unexplored. This study analyzed the correlation between NSCLC and V. parvula abundance based on 16 s rRNA sequencing results. The effects of V. parvula on the progression of lung adenocarcinoma were observed in vivo and in vitro using a C57 bl/6j mouse tumor-bearing model, a bacterial cell co-culture model, combined with transcriptome sequencing, and a TCGA database to explore and validate the growth promotion of lung adenocarcinoma by V. parvula and its molecular mechanism. 16 s rRNA sequencing revealed that V. parvula was significantly enriched in lung adenocarcinoma. In vivo, V. parvula promoted the growth of lung adenocarcinoma in mice by suppressing the infiltration of tumor-associated T lymphocytes and peripheral T lymphocytes. It showed a higher affinity for lung adenocarcinoma in vitro and promoted lung adenocarcinoma cell proliferation through adhesion or intracellular invasion. Further analysis of differential gene expression and KEGG enrichment by transcriptome sequencing revealed that V. parvula induced CCN4 expression and activated NOD-like receptor and NF-κB signaling pathway in lung adenocarcinoma cells. Further analysis clarified that V. parvula promoted activation of the NF-κB pathway via Nod2/CCN4 signaling, which promoted lung adenocarcinoma cell proliferation. Thus, V. parvula mediates activation of the Nod2/CCN4/NF-κB signaling pathway to promote non-small cell lung adenocarcinoma progression, thereby providing a potential target for diagnosing and treating lung adenocarcinoma.

Indexed as

16 s rRNA sequencingCCN4 expressionLLC cellsLung adenocarcinomaVeillonella parvula

Identifiers

PMID37452162
PMCPMC10349017
OpenAlexW4384282281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.